RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company focused on tissue protection and repair with an extensive portfolio of product candidates for first-in-class therapeutic peptides.
June 29, 2009 NYSE Amex Accepts RegeneRx Plan of Compliance
June 22, 2009 RegeneRx Working with U.S. Military to Test Tβ4 Against Exposure to Chemical Agents in the Eye
May 5, 2009 RegeneRx Receives Australian Patent for Treating Eye Disorders with Tβ4